Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Recruiting · NCT06246396 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Florida
View the official record on ClinicalTrials.gov →Interventions studied
Minocycline HydrochloridePlacebo
What this trial is about
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥18 years
- Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
- The participant agrees to have all study procedures performed
Exclusion criteria
- Known hypersensitivity or contraindication to minocycline or other tetracyclines
- Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
- Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation
- Known secondary hypertension
- History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
- History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year
- History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
- Evidence of alcoholism or drug abuse
- Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
- Current pregnancy or anticipated pregnancy during the study.
Where it is running
1 location listed across 1 US state.
- UF Clinical Research Center (UF CRC) - CTSI - Gainesville, Florida, United States